FREE BONUS REPORT(S): When you buy below report, you may pick 1 additional cancer report for free from this list (Value: 2,468 USD)
Introduction
The Japanese Merger Analysis Tool models the potential outcome of a merger between any of the 15 Japanese pharma companies tracked by PharmaVitae. Users can retain or divest specific products, rationalize forecasts, analyze the resulting company by forecast therapeutic and strategic measures, and compare the merged company with its pre-merger partners or any of the 15 tracked companies
Reasons to Purchase
Model merged portfolios at drug level, to establish the commercial potential and viability of the merged portfolios and development pipelines
Compare a virtual company directly with its pre-merger partners, to provide strategic insight into the potential of the prospectively-merged company
Decide which products to retain or divest, then forecast ethical sales by drug and therapy area to 2010 for the virtually merged company
